Rapid phenotyping of knockout mice to identify genetic determinants of bone strength

Bernard Freudenthal¹, John Logan¹, Sanger Institute Mouse Pipelines², Peter I Croucher², Graham R Williams¹ and J H Duncan Bassett¹

¹Molecular Endocrinology Laboratory, Department of Medicine, Imperial College London, London, UK
²Mouse Pipelines, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
³Garvan Institute of Medical Research, Sydney, New South Wales, Australia

Abstract

The genetic determinants of osteoporosis remain poorly understood, and there is a large unmet need for new treatments in our ageing society. Thus, new approaches for gene discovery in skeletal disease are required to complement the current genome-wide association studies in human populations. The International Knockout Mouse Consortium (IKMC) and the International Mouse Phenotyping Consortium (IMPC) provide such an opportunity. The IKMC generates knockout mice representing each of the known protein-coding genes in C57BL/6 mice and, as part of the IMPC initiative, the Origins of Bone and Cartilage Disease project identifies mutants with significant outlier skeletal phenotypes. This initiative will add value to data from large human cohorts and provide a new understanding of bone and cartilage pathophysiology, ultimately leading to the identification of novel drug targets for the treatment of skeletal disease.

Introduction

A novel strategy for osteoporosis gene discovery

Studies of human monogenic extreme phenotype disorders have been instrumental in discovering genetic and molecular mechanisms of common diseases including obesity and diabetes (Yamagata et al. 1996, Montague et al. 1997). However, collection of human extreme phenotype cohorts takes many years and requires significant effort and financial resource. A new approach to osteoporosis gene discovery involves systematic identification of extreme skeletal phenotypes in mutant mouse lines that carry single-gene knockouts representing all the known protein-coding genes. This approach has been made possible by the International Knockout Mouse Consortium (IKMC), whose aim is to disrupt each of the protein-coding genes in C57BL/6 mice, and the International Mouse Phenotyping Consortium (IMPC) that has established a multidisciplinary and broad primary phenotype screen to characterise these mutant mice. By using samples from mice that have undergone the IMPC phenotyping pipeline, a bespoke rapid-throughput multi-parameter skeletal phenotyping platform has been applied systematically to detect significant phenotypes by screening minimal number of samples. This phenotyping programme exploits the excellent replication of human skeletal disease in mice, and novel susceptibility genes can be validated by interrogating human osteoporosis cohorts.

Key Words

osteoporosis, bone, genetics, gene discovery
‘Known unknowns’ in osteoporosis

Osteoporosis is a worldwide healthcare problem that causes up to 9 million fractures annually (Johnell & Kanis 2006). Within the EU, it is estimated that osteoporosis affects 30 million people and osteoporotic fractures cost €37 billion annually (Hernlund et al. 2013). These numbers are projected to rise with the increasing elderly population. Osteoporotic hip fractures are associated with a significant rise in mortality (Sattui & Saag 2014), especially during the year following fracture when it is estimated to be 8–36% (Abrahamsen et al. 2009).

The most important risk factors for osteoporotic fracture are low bone mineral density (BMD) (clinically assessed by dual-energy X-ray absorptiometry (DEXA or DXA)), increasing age and history of fracture (Johnell et al. 2005). There are two key determinants of adult BMD: the peak bone mass attained in early adulthood and the rate of bone loss during ageing. Variation in BMD has a large heritable genetic component. This is known from observations of familial clustering of osteoporosis (Seeman et al. 1989, Keen et al. 1999) and from twin studies that have calculated that the heritable contribution lies between 40 and 90% (Mitchell & Yerges-Armstrong 2011). The heritable contribution to variance in BMD is greatest in early adulthood (Gueguen et al. 1995), yet variation in the rate of bone loss per se is also genetically determined (Kelly et al. 1993). Thus, genetic mechanisms contribute significantly to the risk of osteoporosis. Nevertheless, the known BMD-associated genetic variants account for only 5.8% of the total variance (Estrada et al. 2012), indicating that the majority of susceptibility genes have yet to be identified.

Gene discovery from skeletal extreme phenotypes

Intrinsic and extrinsic factors, systemic hormones, neuronal innovation and mineral homeostasis can all affect bone mass. Significantly, many of the genes and signalling pathways involved in the intrinsic regulation of bone turnover and bone mass have been identified by the study of human monogenic disorders associated with extremes of BMD (Table 1). In traditional gene discovery, the loci of causative alleles would be identified by linkage analysis in the families of index cases, followed by positional cloning of the relevant genes (Alonso &Ralston 2014). Such studies have identified the two key regulatory pathways – canonical Wnt signalling and receptor activator of nuclear factor kappa-B ligand (RANKL)/RANK/osteoprotegerin (OPG) that respectively regulate the function of osteoblasts and osteoclasts. Both these pathways have subsequently been targeted by novel osteoporosis treatments.

The canonical Wnt/β-catenin signalling pathway is the key regulator of osteoblasts, which mediate bone formation (Balemans et al. 2001, Gong et al. 2001, Boyden et al. 2002, Little et al. 2002, Glass et al. 2005). The major Wnt antagonist sclerostin (SOST) was first identified by studying subjects with high bone mass due to sclerosteosis and Van Buchem disease (Balemans et al. 2001, Brunkow et al. 2001). The importance of Wnt signalling was further highlighted by the discovery of activating and inactivating mutations of the Wnt co-receptor LRPS, which results in high and low bone mass, respectively (Johnson et al. 1997, Little et al. 2002).

The RANK-RANKL-OPG pathway regulates osteoclasts, which mediate bone resorption. This signalling pathway was discovered in a functional screen of tumour necrosis factor (TNF)/TNF receptor superfamily members. OPG is an endogenous inhibiting decoy receptor of RANKL related to the TNF receptor. In vivo overexpression of OPG in mice was found to cause osteopetrosis due to impairment of the later stages of osteoclast differentiation (Simonet et al. 1997). Subsequently, human osteopetrosis phenotypes with increased BMD were found to be caused by mutations of RANK, RANKL and other related genes involved in osteoclast differentiation (Coudert et al. 2015).

Regulatory mechanisms in bone turnover

Knowledge of the signalling pathways that regulate bone turnover is essential for understanding the pathophysiology of osteoporosis. The manifest complexity of the signalling pathways and networks that regulate the cellular processes involved in dynamic bone turnover is significant as small differences in function of individual components, including those not yet discovered, may have a combined effect on heritable risk of osteoporosis. The opposing processes of bone resorption and formation are tightly regulated by critical mechanisms including the Wnt signalling and RANKL/RANK/OPG pathways (Fig. 1). At the cellular level, bone remodelling takes place in multicellular units, which comprise co-located osteoclasts and osteoblasts within a bone remodelling cavity (Raggatt & Partridge 2010). The bone remodelling cycle is initiated by osteocytes in response to altered mechanical loading (Nakashima et al. 2011), local microdamage and systemic factors such as parathyroid hormone (Goldring 2015). Unloading stimulates expression of RANKL and the Wnt inhibitors sclerostin and Dickkopf-related protein 1 (DKK-1).
Table 1  Monogenic disorders that have identified key skeletal genes in bone remodelling.

| Disease                                      | Clinical features                          | Gene              | Mechanism                                                                 | Reference |
|----------------------------------------------|--------------------------------------------|-------------------|---------------------------------------------------------------------------|-----------|
| Reduced bone mass                            | Osteoporosis-pseudoglioma syndrome (OPPGS) | Reduced bone mass and blindness | Loss-of-function mutations disrupt Wnt signalling and reduce osteoblastic bone formation. | (Gong et al. 2001) |
| Osteogenesis imperfecta                      | Increased bone fragility; blue sclerae in some types | COL1A1, COL1A2, CRTAP, LEPRE, PP1B | Loss-of-function mutations in collagen and collagen-processing proteins cause abnormal osteoid matrix, thereby impairing normal bone formation. | (Baldridge et al. 2008; Sykes et al. 1986; van Dijk et al. 2009) |
| Juvenile-onset Paget disease                 | Short stature, fractures, skull enlargement, progressive deafness | TNFRSF11B (OPG) | Loss-of-function mutations disrupt inhibition of RANKL by osteoprotegerin, causing increased osteoclastic resorption of bone. | (Chong et al. 2003) |
| X-linked osteoporosis                         | Juvenile-onset fractures in males          | PLS3              | Loss-of-function mutations affect Plastin-3, an actin-binding protein. Mechanism osteoporosis is unknown. | (van Dijk et al. 2013) |
| Increased bone mass                          | Osteopetrosis                             | Increased bone mass with fractures | Loss-of-function mutations affecting osteoclast differentiation and function cause reduced bone resorption. | (Frattini et al. 2000; Guerrini et al. 2008; Kornak et al. 2001; Pangrazio et al. 2006; Sobacchi et al. 2007) |
| Sclerosteosis and Van Buchem disease         | Increased bone mass, syndactyly, entrapment neuropathies | SOST              | Loss-of-function mutations affect inhibition of Wnt signalling by sclerostin, causing increased osteoblastic bone formation. | (Balemans et al. 2001) |
| Autosomal dominant high bone mass            | Increased bone density, entrapment neuropathies, square jaw and torus palatinus | LRP5              | Gain-of-function mutation in Wnt co-receptor causes increased osteoblastic bone formation. | (Boyden et al. 2002) |

in osteocytes, thus increasing osteoclastic bone resorption and decreasing osteoblastic bone formation. Repetitive loading can cause fatigue-induced microdamage and focal tissue injury that leads to osteocyte apoptosis, following which pro-osteoclastogenic signalling is initiated by a discrete population of adjacent osteocytes (Kennedy et al. 2012). By contrast, increased mechanical loading decreases expression of sclerostin and DKK-1 in osteocytes and leads to increased osteoblastic bone formation (Robling et al. 2008). In their basal state, osteocytes maintain quiescence by inhibiting osteoclastogenesis by secreting transforming growth factor β (TGFβ) and inhibiting Wnt-activated osteoblastic bone formation by secreting sclerostin (Heino et al. 2002, Tu et al. 2012). If TGFβ levels fall, bone-lining cells become activated and join osteocytes in secreting the cytokines monocyte/macrophage colony-stimulating factor (M-CSF) and RANKL that stimulate recruitment and differentiation of circulating osteoclast monocyte progenitors (Nakashima et al. 2011). Mature multi-nucleated bone-resorbing osteoclasts adhere to the cell surface and create resorption pits in the middle of the multicellular unit. The osteoclasts secrete acid and proteases including cathepsin-K that degrade the bone matrix, leaving demineralised collagen that is resorbed.
by macrophages. Wnt-activated osteoblasts subsequently secrete and mineralise new bone matrix (osteoid) to fill the resorption cavity. When the repair is complete, the bone surface returns to its quiescent state and sclerostin stimulates mineralisation of the new osteoid (Tu et al. 2012).

**Gene discovery drives therapeutic innovation**

Identification of the genes and regulatory networks that determine normal bone formation, maintenance and strength has facilitated the recent development of new targeted treatments to increase BMD and reduce fracture risk. There is a pressing need for new treatment options in osteoporosis as current treatments achieve at best partial relative risk reduction of fracture. Bisphosphonates remain the mainstay of treatment for primary and secondary prevention of osteoporotic fracture, despite the recognition uncommon but significant side effects (Kennel & Drake 2009). Other treatments including strontium ranelate and raloxifene are no longer advocated as first line because of associated cardiovascular risks (Barrett-Connor et al. 2006, Abrahamsen et al. 2014).

New treatments for osteoporosis include small-molecule inhibitors and biological therapies have been developed based on this new understanding of bone turnover. Denosumab is a fully humanised monoclonal antibody to RANKL that mimics the endogenous inhibiting activity of OPG (Lacey et al. 2012). Denosumab is administered by 6-month injection; yet, its use is restricted by high cost and its effects are rapidly reversible. Another new class of osteoporosis drugs are those that target the osteoclast-secreted protease cathepsin-K (Makras et al. 2015). However, most of the cathepsin-K inhibitors have adverse off-target effects, with the exception of odanacatib, which has now successfully completed phase III trials (Bone et al. 2015). Humanised monoclonal antibodies to the Wnt antagonist sclerostin (romosozumab and blosozumab) are in development as new anabolic agents (Shah et al. 2015, Sim & Ebeling 2015). However, since romosozumab is currently in phase III trials and blosozumab has only completed phase II trials, effect on fracture risk is still unknown.

Despite some recent advances, there remains a large unmet need for new therapeutic targets in osteoporosis. Of all the newer targeted treatments, only...
the small-molecule odanacatib is administered orally. The requirement for parenteral subcutaneous administration is an impediment to use of teriparatide and all monoclonal antibody treatments. It is hoped that further advances in knowledge of the complex mechanisms of bone turnover regulation and the genetic basis of the heritability of osteoporosis will enable the accelerated development of new osteoporosis treatments. The current goals in osteoporosis gene discovery must be to identify novel targets with a systematic methodology that may replicate the successes of past studies in Mendelian extreme phenotype cohorts.

**Systematic osteoporosis gene discovery in human studies**

**The Human Genome Project and association studies**

In order to identify novel genes that relate to heritability of osteoporosis systematically, new population-based methodologies were required and have been used extensively. Linkage analysis and positional cloning techniques, used to identify gene mutations in Mendelian disorders, were less successful when applied to population cohorts with low BMD. Several genome-wide linkage studies were performed on high and low BMD cohorts to detect quantitative trait loci (QTLs) that regulate BMD. However, these studies produced heterogeneous results, and when combined in a meta-analysis, none of the QTLs reached genome-wide significance (Ioannidis et al. 2007).

It was the subsequent development of GWAS analysis that made it possible to search for genetic influences on complex polygenic traits such as osteoporosis. After the first sequence of the human genome was completed, the International HapMap Project was established to catalogue the common genetic variation between the genomes of 249 individuals in four different populations, leading to the mapping of over 1 million single-nucleotide polymorphisms (SNPs) within the human genome (International HapMap Consortium 2005). A major aim of the HapMap Project was to facilitate the study of the contribution of normal genetic variation to the inheritance of complex polygenic phenotypic traits such as osteoporosis (Frazer et al. 2009). In GWAS analyses, large population-based cohorts containing many thousands of subjects are genotyped by chip-based microarrays for the presence of millions of SNPs, or alternatively copy-number variants (CNVs). These data are used to perform hypothesis-free significance testing for association of the inherentance of the SNPs or CNVs with disease phenotypes (Manolio 2010).

To date, GWAS have identified more than 60 loci associated with BMD, confirming the polygenic nature of this variable (Richards et al. 2012). Less data are, however, available for fracture risk than BMD (Mitchell & Streeten 2013). Although estimation of areal BMD by DEXA scanning is a good predictor of fracture susceptibility, it does not necessarily reflect bone quality as DEXA does not account for bone geometry, size and strength (Marshall et al. 1996).

Population-based genetic cohort studies have significant limitations in relation to osteoporosis gene discovery. When GWAS data are combined in meta-analyses, variability in the characterisation of phenotype can be an important confounder, and population studies are also limited by the quality and reproducibility of the phenotyping (Visscher et al. 2012). Many of the genomic loci identified by GWAS map to genes in pathways already known to be related to bone biology, such as the Wnt/β-catenin, RANK-RANKL-OPG, mesenchymal stem cell differentiation and SOX9-regulated endochondral ossification pathways (Mitchell & Streeten 2013). Overall, GWAS analysis has not yet led to the discovery of major new mechanisms that regulate bone turnover regulation and predispose to osteoporosis. Indeed, contrary to initial expectations, GWAS analyses failed to discover sufficient determinants of polygenic heritable traits to enable individual disease risk prediction. An osteoporosis risk prediction model using the combined weighted effects of 63 BMD-decreasing alleles in a population-based study containing 2836 women explained only 5.8% of the total variance in femoral neck BMD (Estrada et al. 2012).

A further difficulty in identifying susceptibility genes by GWAS analysis arises from the fact that identified SNPs are rarely functionally significant, although their loci may identify adjacent pathogenic pathways and mechanisms. The co-association of the SNP with the disease phenotype indicates that it is in linkage disequilibrium with a gene (or a non-coding regulatory element) that has a constituent functional role that is contributory to the phenotype (Cantor et al. 2010). The size of the detected effect is itself of little importance, and it is typical that the effect size of individual identified loci is inversely proportional to the population sample size in a GWAS. The mean effect size of SNPs identified in the largest osteoporosis GWAS meta-analysis to date was 0.048 standard deviations (s.d.s) and the largest effect size was 0.1 s.d. (Estrada et al. 2012, Zheng et al. 2015).
To address the limitation that standard GWAS microarrays only test common genetic variants (minor allele frequency (MAF) > 5%), larger reference panels have been created from the recent UK10K and 1000 Genomes projects. ‘Next-generation sequencing’ techniques have enabled direct imputation of low-frequency coding and non-coding variants found by whole-genome sequencing of large osteoporosis cohorts. Thus far, only one low-frequency variant with genome-wide significance for skeletal disease has been identified by these techniques (Zheng et al. 2015). The variant is near a novel locus, engrailed homeobox-1 (EN1) and has an estimated effect size on lumbar spine BMD of 0.2 s.d.s, which is four-fold larger than the mean effect size of previously reported common variants.

Transcriptomics and osteoporosis

One limitation of the GWAS data is that the majority of identified SNPs may be located within poorly annotated regulatory elements in intron or intergenic non-coding regions (Cooper 2010). Indeed, it is increasingly appreciated that heritable variation of osteoporosis risk is manifest in more ways than just variation in the coding sequence of genes. Expression levels of RNA and proteins, as regulated by gene regulation networks and epigenetic control, are also of great importance. Consequently, study of variations in levels of RNA transcripts has also been applied to identify new molecular mechanisms and signalling pathways involved in regulation of BMD. Furthermore, it is anticipated that analysis of non-coding RNAs will lead to a better understanding of the significance of intergenic loci identified by GWAS (Hangauer et al. 2013).

Transcriptomic studies have used high-throughput microarray analysis to quantify mRNA expression in osteoporotic and non-osteoporotic human bone, precursor mesenchymal stem cells and primary osteoblast cultures (Wu et al. 2013). In a microarray study of gene expression in human osteoblasts, 1606 genes were found to be differentially expressed between osteoporotic and non-osteoporotic subjects (Trost et al. 2010). Many of these genes had been identified previously by GWAS analysis, but several were new and could not have been predicted. Thus, osteoporosis transcriptomics studies have confirmed that numerous distinct signalling pathways are involved in the regulation of bone turnover and bone mass. However, replication of these studies has been difficult and confounded by limited sample size, poor signal to noise ratio and technical limitations of commercially available microarrays (Wu et al. 2013). Future work will increasingly use next-generation sequencing methods, which do not require a priori knowledge of the transcriptome sequence and have a superior sensitivity, specificity and dynamic range in comparison with current microarrays (Vikman et al. 2014). With use of advanced statistical techniques, it is possible to discover new splice variants and non-coding sequences. Despite these advances, RNA-sequencing approaches require preparation of high-quality RNA from sufficient numbers of physiologically relevant samples. Accordingly, it is not yet possible to study gene expression in osteoporosis using large population-based sample sizes, and RNA sequencing is likely to be most useful in the analysis of animal models.

Proteomics

Proteomics allows the simultaneous analysis of all proteins in a sample of cells by antibody-based purification and mass spectrometry techniques. A number of studies have demonstrated differential regulation of cellular protein expression in osteoporosis (Wu et al. 2013). Most of the studies have been performed in vitro using osteoblast and osteoclast cell cultures. Human proteomic studies have predominantly used peripheral circulating monocytes as precursors to osteoclasts (Deng et al. 2011a,b), or bone marrow-derived mesenchymal stem cells (Choi et al. 2010). However, reproducibility of such results has been limited.

Epigenomics

The heritability of osteoporosis may also be mediated by epigenetic gene regulation, in which gene or allele expression is ‘imprinted’ by DNA methylation and histone modifications (Holroyd et al. 2012). Epigenome-wide studies have only recently been performed in relation to osteoporosis. Transcriptome gene expression microarray, epigenomic miRNA microarray and methylome sequencing were simultaneously performed using circulating monocytes from five subjects with low hip BMD and five with high BMD, in order to integrate transcriptomic and epigenomic data (Zhang et al. 2015). The aim is to reveal the higher regulatory mechanisms (‘interaction network modules’) underlying the genetic control of osteoporosis heritability. However, the problems of low sample number and difficulty of accessing human skeletal tissues are important limitations in such approaches.
The mouse as an essential tool for osteoporosis gene discovery

Human population studies have been limited in their ability to identify novel genetic determinants of osteoporosis, although they have confirmed that bone-regulating genes identified in the study of rare extreme phenotypes contribute to the complex heritability of secondary osteoporosis. Across the breadth of human biology, there are huge knowledge gaps as the function of most genes and the heritability of many complex diseases remain unknown (Schofield et al. 2012). In order to meet the challenge of discovering the functional relationship between human genes and their phenotypic effects, powerful new experimental tools are required. Model organisms provide the ability to draw genetic and physiological parallels to human genetic systems, and their use has complemented many advances in human molecular genetics. In particular, an extensive range of techniques for experimental genetic manipulation have been developed in mice.

The genome of the C57BL/6J mouse strain was sequenced in 2002 (Waterston et al. 2002), shortly after the human genome. Thus, laboratory mice provide a unique resource that can be used to generate genetically modified models of human diseases (Schofield et al. 2012). Currently, 17,055 mouse–human homologs have been annotated in the Mouse Genome Database (Dolan et al. 2015). Critically, the selective mutation or deletion (‘knockout’) of individual genes in mice can be used to identify and characterise gene function in vivo.

International knockout mouse programmes

Such is the utility of knockout mice that a number of mutagenesis programmes have collaborated to cryo-preserve mouse lines for unrestricted use by the research community. The IKMC was established with the goal of creating a complete resource of reporter-tagged null mutations for all protein-coding genes in C57BL/6 mouse ES cells by 2021 (Collins et al. 2007).

The IKMC-targeted mutagenesis techniques involve use of bacterial artificial chromosome (BAC)-based ‘Knockout-First’ conditional ready gene targeting vectors that use homologous recombination to incorporate a lacZ selection cassette in the relevant targeted sequence (Fig. 2) (Testa et al. 2004). This enables the generated mouse lines to be versatile and powerful tools for research. The Knockout-First vectors combine two functions by creating either a reporter-tagged knockout or a conditional mutation if the gene-trap cassette is removed by FLP recombinase, thereby reverting the knockout mutation to wild type, although with addition ofloxP sites that flank a functionally critical exon (Skarnes et al. 2011). The consequence of this is that temporal or tissue-specific analysis of gene function can be performed by crossing mice bearing the allele containing theloxP-flanked (‘floxed’) critical exon with transgenic mice that express Cre recombinase under control of a constitutive or inducible cell type-specific promoter.

Pipeline phenotyping of knockout mice

The IKMC provides readily available knockout mice that can be used for functional investigation of candidate genes, for example in loci identified by GWAS analysis (Cox & Church 2011). The singular ambition to deduce the function of all the genes discovered in the Human Genome Project, however, has led to the development of ambitious large-scale systematic phenotyping programmes of all knockout mouse lines with deletions of homologs to human genes (Bradley et al. 2012). These projects enable...

Figure 2
Knockout-first strategy for creating dual-purpose knockout/conditional alleles. Bacterial artificial chromosome (BAC)-based targeting vectors are inserted by homologous recombination into mouse ES cells. Recombination steps with Cre or Flp recombinase are illustrated. (A) Knockout-first allele (reporter-tagged insertion allele). Gene-trap knockout is generated using a targeting cassette containing the marker genes lacZ and neomycin. A separateloxP site is inserted on the other side of a critical exon (Exon 2). (B) Conditional allele (post-Flp). By crossing mice with a Flp deleter strain, the gene-trap knockout is reversed and a floxed allele is created, enabling conditional Cre recombinase-mediated gene inactivation. (C) Deletion allele (post-Flp and Cre with no reporter).
the study of the extreme phenotype potential of every known coding gene, thereby providing the potential for systematic discovery of novel critical skeletal genes. What would otherwise have been individually impossible in terms of resources and complexity has been achieved by the coordination and the standardisation of a series of international programmes to form a major worldwide project The IMPC (Koscielny et al. 2014).

The international phenotyping pipeline incorporates standardised and validated tests with protocols shared by contributing mouse clinics across the world (de Angelis et al. 2015). The pipelines incorporate 20 phenotyping tests that capture 413 parameters and cover all systems divided between the categories of morphology, metabolism, cardiovascular, bone, neurobehavioural and sensory, haematology, clinical chemistry and allergy/immune. The phenotyping tests are performed at defined times in the first 16 postnatal weeks and require a minimum cohort of seven male and seven female mice (Brown & Moore 2012). New statistical models have had to be developed, in order to ensure the reproducibility of the multivariate data generated (Karp et al. 2015). In an initial report of phenotype data on mutant lines representing 320 unique genes, 83% of mutant lines were outliers (de Angelis et al. 2015). Of the 250 lines reported in an early phase of the phenotyping pipeline contributed by the IMPC member Wellcome Trust Sanger Institute (WTSI), 104 were lethal or sub-viable and were phenotyped as heterozygotes; nonetheless, haploinsufficient phenotypes were detected in 38 of these lines (White et al. 2013). Ongoing results from the international multicentre phenotyping projects are released at http://www.Mousephenotype.org/.

Skeletal phenotyping screen of knockout mouse lines

Ancillary IMPC projects

The systematic phenotyping of knockout mice by the IMPC has already begun to reveal genes whose deletion has an effect on BMD (estimated by whole-body DEXA), implying a functional role in bone development and skeletal physiology. To date, 79 out of 1820 lines have an outlier phenotype associated with decreased BMD (IMPC phenotype MP:0000063) and 41 lines have increased BMD (IMPC phenotype MP:0000062). However, a major limitation is the poor sensitivity and specificity of DXA for the analysis of the mouse skeleton (Holmen et al. 2004). Other skeletal parameters included in the IMPC phenotyping are body length and X-ray skeletal survey to detect gross anatomical variation. As critical determinants of healthy bone include bone mineral content (BMC), bone strength and other three-dimensional morphological parameters, the IMPC phenotype screen lacks the precision required for comprehensive detection of bone structure and strength abnormalities.

To address these limitations, a number of ancillary specialist screens have been established. The Origins of Bone and Cartilage Disease (OBCD) project (http://www.boneandcartilage.com/) is performing a multi-parameter skeletal phenotyping screen of mouse lines generated by the WTSI, an IMPC partner institution, using methods that give critical functional and structural information regarding skeletal phenotype (Fig. 3). The goals of the OBCD project are to (i) identify novel pathways regulating normal bone development, maintenance and resilience; (ii) uncover new genetic determinants of osteoporosis; and (iii) provide in vivo models to elucidate their molecular basis and investigate novel treatments.

New imaging and biomechanical techniques have been developed to detect abnormalities of bone structure and strength that parallel those occurring in human disease. Cross-disciplinary collaboration with the fields of biophysics, microimaging and statistics has enabled development of a bespoke rapid-throughput multi-parameter bone phenotyping platform (Fig. 4) (Bassett et al. 2012a, Esapa et al. 2012).

OBCD phenotyping techniques

Limbs and caudal vertebrae from knockout mice are analysed at 16 weeks of age after completion of the IMPC phenotyping pipeline at WTSI. No additional animals are required for the OBCD screen, and transportation of samples is logistically simple. Each batch of 75 samples, which contains both mutants and wild-type controls, is analysed blind with genotypes only being assigned on completion of the batch’s phenotyping.

Digital X-ray microradiography is performed on femurs and tail vertebrae, and the images are analysed to determine bone length and BMC (Bassett et al. 2012b). X-ray images are recorded at 10µm pixel resolution using a Faxitron MX20 specimen radiography system. Bone length is determined using ImageJ 1.41 software (http://rsb.info.nih.gov/ij/). The relative mineral content of the calcified tissues is quantified after calibrating each image to three internal standards. Measurement of the median grey level is used to identify outliers with increased or decreased BMC.
Micro-CT analysis has been optimised to determine femoral trabecular bone parameters including trabecular bone volume as proportion of tissue volume (BV/TV), trabecular thickness and trabecular number. In addition, cortical bone parameters of cortical thickness, cortical diameter and cortical volumetric BMD are calculated (Bouxsein et al. 2010, Esapa et al. 2012). A Scanco micro-CT 50 system allows automated rapid-throughput high-resolution imaging. Three-dimensional quantitative image analysis is performed using clearly defined regions of interest and compared with reference data.

Biomechanical variables of bone strength and toughness are derived from femur three-point bend test load–displacement curves and tail vertebrae compression testing (Esapa et al. 2012). Load–displacement curves are plotted so that yield load, maximum load and fracture load can be determined. Stiffness is determined from the slope of the linear (elastic) part of the load–displacement curve.

**Pilot study**

Before commencing the OBCD skeletal phenotyping screen, a prospective pilot study of 100 unselected knockout mouse lines was undertaken (Bassett et al. 2012a). As part of the pilot project, it was necessary to determine reference ranges and coefficients of variation for each of the study parameters for female C57BL/6 wild-type mice. Principal component analysis was used to optimise the detection of significant skeletal phenotypes in multivariate outliers, as significant abnormal phenotypes may only be detected when variances in all parameters are considered (Rousseeuw & Van Zomeren 1990).
As reference data were established in a large number of genetically identical wild-type mice, power calculations determined that samples from only two animals were required to detect a significant abnormality that represents an outlier phenotype.

In the pilot study of 100 knockout mouse lines, nine new genetic determinants of bone mass and strength were identified, none of which had been identified previously in GWAS analysis of osteoporosis cohorts or could have been predicted a priori. Analysis of the contrasting patterns of abnormality amongst the different phenotypic parameters enabled phenotypes to be categorised in a way that could be mapped directly to human skeletal disease. Bones were classified as either (i) weak but flexible with low BMC (as in osteoporosis), (ii) weak and brittle with low BMC (typical of matrix disorders including osteogenesis imperfecta) or (iii) strong but brittle with high BMC (high bone mass disorders such as osteopetrosis). The nine new determinants of bone mass and strength identified included five genes whose deletion results in low bone mass (Bbx, Cadm1, Fam73b, Prpsap2 and Slc38a10) and four whose deletion results in high bone mass (Asxl1, Setdb1, Spns2 and Trim45). The study also confirmed the low bone mass phenotype identified previously in Sparc knockout mice (Delany et al. 2000). Three of the knockout lines carried heterozygous mutations (Asxl1, Setdb1 and Trim45), whereas the rest were homozygotes.

**Other skeletal phenotyping programmes**

Although the OBCD pilot study was the first approach to be published, similar phenotype screening methods have been undertaken by others. Lexicon Pharmaceuticals, Inc. recently published selected results from a screen of knockout mouse lines to search for potential osteoporosis drug targets (Brommage et al. 2014). This phenotyping screen included three techniques (skeletal DEXA of live mice, micro-CT of dissected bones and histological...
examination of decalcified bones). Ten novel genes were named, and three further unnamed novel genes coding for apparent potential osteoporosis drug targets were alluded to.

The IMPC-constituent knockout mouse programme (KOMP) of the Jackson Laboratory has recently commenced its own skeletal phenotyping project that involves rapid micro-CT and automated bone and joint cartilage histology (http://bonebase.org/). This screen focuses on detecting evidence of variations in skeletal cellular function. Histomorphometry is performed by a recently innovated high-throughput process that involves computer-automated signal detection for the particular cell type-specific stains. Data are accrued by automated analysis that calculates the percentage of the bone surface containing the light signal from each stain, thereby suggesting the pattern of disruption of cellular activity in the trabecular bone of the femur and vertebra that may account for the architectural observations seen in micro-CT (Hong et al. 2012). Besides phenotyping inbred lines from the IKMC mutant mouse repository (Yoshiki & Moriwaki 2006), the Bonebase phenotyping project is phenotyping mouse lines from the ‘Collaborative Cross’ project, which has created hybrids from eight founder inbred strains in order to perform genetic mapping studies to identify the QTLs that contribute to complex traits and diseases (Bogue et al. 2015). Similarly, Bonebase is also studying ‘diversity outbred’ lines created to produce a genetic resource to facilitate high-resolution mapping of the effects of allelic heterozygosity that replicates the complexity of the human population (Svenson et al. 2012).

Current OBCD project goals

The OBCD project is currently funded by a Wellcome Trust Strategic Award to undertake skeletal phenotyping of all knockout mouse lines generated at the Sanger Institute. Results are available at the OBCD website and also uploaded to the IMPC mouse portal. Although the IMPC parent project is powered robustly to assess and catalogue the unknown pleiotropic effects of gene deletion, the OBCD screen is designed for rapid-throughput hypothesis generation. Once extreme phenotypes are detected, they can be selected for additional in-depth analysis.

Detailed analysis of extreme phenotypes

Knockout mice with extreme skeletal phenotypes are considered for additional detailed analysis and the selection procedure follows a specific algorithm (Fig. 5). Although novelty is a key criterion, phenotype severity, biological plausibility, human disease association and experimental tractability are also critical considerations (Duncan et al. 2011, van Dijk et al. 2014).

Detailed phenotyping includes skeletal analysis during prenatal and postnatal development, at peak bone mass and in adulthood. Juvenile analysis establishes the role of gene in skeletal development and growth, whereas adult analysis establishes its role in skeletal maintenance and repair. Gene expression pattern of the deleted gene can be investigated by LacZ staining, taking advantage of the reporter gene included in the knockout-first gene targeting cassette. Temporal expression can be established at different time points in embryonic and adult mice.

To determine the cellular basis of the abnormal phenotype, static and dynamic histomorphometry can be performed to identify abnormalities of osteoclastic bone resorption and osteoblastic bone formation (Bassett et al. 2010). Primary chondrocytes, osteoblasts and osteoclasts, cultures from wild-type and mutant mice can be undertaken to determine the consequences of gene deletion on cell proliferation, differentiation and function (Bassett et al. 2008). If these studies suggest that the phenotype is a consequence of a defect in a specific bone cell lineage, conditional deletion of the gene in the specific cell type may be used to determine if the phenotype of the global knockout is recapitulated. By crossing the knockout mouse line with an Flp deleter strain, the gene-trap knockout is reversed and a loxP-flanked (‘floxed’) allele is generated (Fig. 2). Subsequently, floxed mice can be crossed with bone cell lineage-specific Cre strains (Murray et al. 2012) (Table 2).

To determine the molecular basis of the skeletal phenotype, the effect of the gene knockout on global gene expression can be examined by whole-genome microarray analysis of RNA extracted from bones of the knockout mice or from cell cultures. Cluster analysis is performed to identify patterns of gene expression that suggest involvement of specific signalling pathways. In addition, whole transcriptome analysis can be performed by RNA sequencing with next-generation sequencing techniques. Bioinformatics analysis can determine the effect of the gene deletion on complex gene networks including alternative splice variants and regulatory elements such as non-coding RNAs (Vikman et al. 2014).

Although the rapid-throughput skeletal phenotyping screen is a powerful technique to identify new gene that regulates bone mineralisation and strength, it has
Gene knockouts causing significant skeletal phenotypes

Target selection criteria

**Biological importance:**
- Novelty of target
- Size of phenotype
- Expression pattern of gene

**Expected yield:**
- Known function of gene
- Experimental tractability

**Translational potential:**
- Association with human monogenic disease
- Association of SNPs with BMD and fracture in human cohorts

In-depth analysis of selected knockout lines

Detailed phenotyping:
- Determine the developmental onset of the defect

Cellular mechanisms:
- Differentiate defects in osteoclast, osteoblast, chondrocyte and osteocyte function

Molecular mechanisms:
- RNaseq & bioinformatics

---

limitations related to (i) the use of mice as a model system, (ii) analysis of only knockout animals and (iii) the specific skeletal phenotyping methods selected.

There are well-described differences in bone structure, bone remodelling and hormonal changes between humans and mice. Despite these differences, key molecules that regulate bone and cartilage have been shown to have the same functions in mice and humans and many inherited skeletal disorders are recapitulated in genetically modified mice. In addition, although there is no mouse menopause, the consequences of oestrogen deficiency can still be studied in mice using the ovariectomy provocation model. Furthermore, if extreme skeletal phenotypes are identified in mouse knockout lines, genetic variation in the homologous human genes can be investigated in large well-characterised human populations such as those included in the GEnetic Factors for OSteoporosis Consortium (GeFOS) (http://www.gefos.org/).

The IKMC/IMPC knockout strategy aims to determine the physiological role of genes by identifying the pathophysiological consequences of loss-of-function but will not identify phenotypes associated with gain-of-function mutations, epigenetic modifications or other environmental risk factors. Nevertheless, if a significant skeletal phenotype is detected in knockout animals, the consequences of gain-of-function mutation could then be studied by using CRISPR-Cas-based targeted gene-editing techniques to generate mouse models (Gaj et al. 2013, Sander & Joung 2014).

**Table 2** Examples of cell-specific promoter-driven Cre recombinases in available transgenic mouse lines

| Cell type       | Mouse lines expressing Cre-recombinase with cell-specific promoter | Equivalent inducible Cre-recombinase | References                                                                 |
|-----------------|--------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------------|
| Osteoblasts     | OC-Cre, Col1a1-Cre                                                 | Col1-CreER<sup>T2</sup>             | (Kim et al. 2004; Nakanishi et al. 2008; Zhang et al. 2002)                |
| Osteoclasts     | Ctsk-Cre, LysM-Cre                                                 | Ctsk-CreER<sup>T2</sup>             | (Chiu et al. 2004; Sanchez-Fernandez et al. 2012)                         |
| Osteocytes      | Dmp1-Cre                                                           | Dmp1-CreER<sup>T2</sup>             | (Lu et al. 2007; Powell et al. 2011)                                      |
| Chondrocytes    | Col2-Cre                                                           | Agc1-CreER<sup>T2</sup>             | (Henry et al. 2009; Yoon et al. 2005)                                     |
Robust, sensitive and specific skeletal phenotyping screening requires a combination of complementary, rapid-throughput methodologies but can never be exhaustive. However, once an extreme phenotype has been identified and prioritised for further detailed analysis, other important determinants of bone strength such as tissue mineralisation and bone geometry can be determined by quantitative backscattered electron scanning electron microscopy (Bassett et al. 2010) and statistical shape modelling (Yang et al. 2006), respectively.

In conclusion, systematic, rapid-throughput skeletal phenotyping of genetically modified mice is an exciting new approach that complements human population studies of complex polygenic disorders and has the potential to identify important new signalling pathways involved in the pathogenesis of skeletal disease.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding
This work was supported by a Wellcome Trust Strategic Award (grant number 101123) and a Wellcome Trust Project Grant (grant number 094134).

References
Abrahamsen B, van Staa T, Ariely R, Olson M & Cooper C 2009 Excess mortality following hip fracture: a systematic epidemiological review. Osteoporosis International 20 1633–1650. (doi:10.1007/s00198-009-0920-3)
Abrahamsen B, Grove EL & Vestergaard P 2014 Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporosis International 25 757–762. (doi:10.1007/s00198-013-2409-4)
Alonso N & Ralston SH 2014 Unveiling the mysteries of the genetics of osteoporosis. Journal of Endocrinological Investigation 37 925–934. (doi:10.1007/s00335-014-0497-9)
Baldridge D, Swarze U, Morello R, Lennington J, Evans M, Lawson MA, Croucher P, St Germain D, et al. 2010 Optimal bone strength and mineralization requires the type 2 thyrotrpon deiodinase in osteoblasts. PNAS 107 7604–7609. (doi:10.1073/pnas.0911346107)
Bassett JH, Gogakos A, White JK, Evans H, Jacques RM, van der Spek AH, Ramirez-Solis R, Ryder E, Sunter D, Boyd J, et al. 2012a Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength. PLoS Genetics 8 e1002858. (doi:10.1371/journal.pgen.1002858)
Bassett JH, van der Spek A, Gogakos A & Williams GR 2012b Quantitative X-ray imaging of rodent bone by Faxitron. Methods in Molecular Biology 816 499–506. (doi:10.1007/978-1-61779-415-5_29)
Bogue MA, Churchill GA & Chesper EJ 2015 Collaborative cross and diversity outbred data resources in the mouse phenome database. Mammalian Genome 26 511–520. (doi:10.1007/s00198-015-9595-6)
Bone HG, Dempster DW, Eisman JA, Greenspan SI, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, et al. 2015 Ondanacatib for the treatment of postmenopausal osteoporosis: development history and participant characteristics of LOFT, the Long-Term Ondanacatib Fracture Trial. Osteoporosis International 26 699–712. (doi:10.1007/s00198-014-2944-6)
Bouxsein ML, Boyd SK, Christiansen BA, Guildberg RE, Jepsen KJ & Muller R 2010 Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. Journal of Bone and Mineral Research 25 1468–1486. (doi:10.1002/jbmr.141)
Boydln DM, Mao J, Belsky J, Mitzenl J, Farhi A, Mitnick MA, Wu D, Insigna K & Liftón RP 2002 High bone density due to a mutation in LDL-receptor-related protein 5. New England Journal of Medicine 346 1513–1521. (doi:10.1056/NEJMoa013444)
Bradley A, Anastassiadis K, Ayadi A, Battey JF, Bell C, Birlin MC, Bottomley J, Brown SD, Bürger A, Bult C, et al. 2012 The mammalian gene function resource: the international knockout mouse consortium. Mammalian Genome 23 880–886. (doi:10.1007/s00335-012-9422-2)
Brommage R, Liu J, Hansen GM, Kirkpatrick LL, Potter DG, Sands AT, Zambrowicz B, Powell DR & Voge P 2014 High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Research 2 14034. (doi:10.1038/boneres.2014.34)
Brown SD & Moore MW 2012 The International Mouse Phenotyping Consortium: past and future perspectives on mouse phenotyping. Mammalian Genome 23 632–640. (doi:10.1007/s00335-012-9427-x)
Brunkow ME, Gardner JC, Van Ness J, Paepert BW, Kovacevich BR, Proll S, Skonerie J, Zhao L, Sabo PJ, Fu Y, et al. 2001 Bone dysplasia scleroestosis results from loss of the SOST gene product, a novel cystine knot-containing protein. American Journal of Human Genetics 68 577–589. (doi:10.1086/318811)
Cantor RM, Lange K & Sinzheimier JS 2010 Prioritizing GWAS results: a review of statistical methods and recommendations for their application. American Journal of Human Genetics 86 6–22. (doi:10.1016/j.ajhg.2009.11.017)
Chiu WS, McManus JP, Notini AJ, Cassidy AB, Zajac JD & Davey RA 2004 Transgenic mice that express Cre recombinase in osteoclasts. Genetics 139 178–185. (doi:10.1007/s00198-002-0401-4)
Choi YA, Lim J, Kim KM, Acharya B, Cho JY, Bae YC, Shin HI, Kim SY & Park KT 2010 Secretome analysis of human BMSCs and identification of SMOC1 as an important ECM protein in osteoblast differentiation. Journal of Proteome Research 9 2946–2956. (doi:10.1021/pr091110q)
Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, Canis J, Seidel J, Tav C, Tuyuz B, et al. 2003 Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between
phenotype and genotype. *Journal of Bone and Mineral Research* **18** 2095–2104. (doi:10.1359/jbmr.2003.18.12.2095)

Collins FS, Rossant J & Wurst W 2007 A mouse for all reasons. *Cell* **128** 9–13. (doi:10.1016/j.cell.2006.12.018)

Cooper DN 2010 Functional intronic polymorphisms: buried treasure awaiting discovery within our genes. *Human Genetics* **8** 284–288. (doi:10.1186/1479-7364-4-5-284)

Couderc AE, de Vernejoul MC, Muraca M & Del Fattore A 2015 Osteopetrosis and its relevance for the discovery of new functions associated with the skeleton. *International Journal of Endocrinology* **2015** 372156. (doi:10.1155/2015/265151)

Cox RD & Church CD 2011 Mouse models and the interpretation of human GWAS in type 2 diabetes and obesity. *Disease Models & Mechanisms* **4** 155–164. (doi:10.1242/dmm.000414)

de Angeli MH, Nicholson G, Selloum M, White JK, Morgan H, Ramirez-Solis S, Sorg T, Wells S, Fuchs H, Fray M, et al. 2015 Analysis of mammalian gene function through broad-based genotypic screens across a consortium of mouse clinics. *Nature Genetics* **47** 969–978. (doi:10.1038/ng.3360)

Delany AM, Amling M, Priemel M, Howe C, Baron R & Canalis E 2000 Osteopetrosis and its relevance for the discovery of new functions associated with the skeleton. *International Journal of Endocrinology* **2015** 372156. (doi:10.1155/2015/265151)

Goldring SR 2015 The osteocyte: key player in regulating bone turnover. *RMD Open* **1** e000049. (doi:10.1136/rmdopen-2015-000049)

Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, et al. 2001 LDL receptor-related protein 5 (LRPS) affects bone accrual and eye development. *Cell* **107** 513–523. (doi:10.1016/S0092-8674(01)00571-2)

Gueguen R, Jouanny P, Guillerm F, Kuntz C, Pourcel J & Siest G 1995 Segregation analysis and variance components analysis of bone mineral density in healthy families. *Journal of Bone and Mineral Research* **10** 2017–2022. (doi:10.1002/jbmr.5650101223)

Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazi A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, et al. 2008 Human osteoclast-poor osteoporosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. *American Journal of Human Genetics* **83** 64–76. (doi:10.1016/j.ajhg.2008.06.015)

Hangauer MJ, Vaughn IV & McManus MT 2013 Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* **9** e1003569. (doi:10.1371/journal.pgen.1003569)

Heino TJ, Hentunen TA & Vaananen HK 2002 Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. *Journal of Cellular Biochemistry* **85** 185–197. (doi:10.1002/jcb.10109)

Henry SP, Jiang CW, Deng JM, Zhang Z, Behringer RR & de Crombrugghe B 2009 Generation of aggrcan-CreERT2 knockin mice for inducible Cre activity in adult cartilage. *Genesis* **47** 805–814. (doi:10.1002/dvg.20564)

Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stemmark J, McCloskey EV, Jonsson B & Kanis JA 2013 Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). *Archives of Osteoporosis* **8** 136. (doi:10.1007/s11657-013-0136-1)

Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berguis BD, Resau JH, Hess JF, Glatt V, Bouxsein ML, AI, M, Warman ML, et al. 2004 Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. *Journal of Bone and Mineral Research* **19** 2033–2040. (doi:10.1359/jbmr.040907)

Holroyd C, Harvey N, Dennison E & Cooper C 2012 Epigenetic influences in the developmental origins of osteoporosis. *Osteoporosis International* **23** 401–410. (doi:10.1007/s00198-011-1671-5)

Hong SH, Jiang X, Chen L, Josh P, Shin DG & Rowe D 2012 Computer-automated static, dynamic and cellular bone histomorphometry. *Journal of Tissue Science & Engineering* **5** (Supplement 1) 004. (doi:10.4172/2157-7552.S1-004)

International HapMap Consortium 2005 A haplotype map of the human genome. *Nature* **437** 1299–1302. (doi:10.1038/nature04226)

Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, F, & McManus MT 2013 Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* **9** e1003569. (doi:10.1371/journal.pgen.1003569)

International HapMap Consortium 2005 A haplotype map of the human genome. *Nature* **437** 1299–1302. (doi:10.1038/nature04226)

Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, F, & McManus MT 2013 Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* **9** e1003569. (doi:10.1371/journal.pgen.1003569)

International HapMap Consortium 2005 A haplotype map of the human genome. *Nature* **437** 1299–1302. (doi:10.1038/nature04226)

Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, F, & McManus MT 2013 Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* **9** e1003569. (doi:10.1371/journal.pgen.1003569)

International HapMap Consortium 2005 A haplotype map of the human genome. *Nature* **437** 1299–1302. (doi:10.1038/nature04226)

Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, F, & McManus MT 2013 Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* **9** e1003569. (doi:10.1371/journal.pgen.1003569)

International HapMap Consortium 2005 A haplotype map of the human genome. *Nature* **437** 1299–1302. (doi:10.1038/nature04226)

Ioannidis JP, Ng MY, Sham PC, Zintzaras E, Lewis CM, Deng HW, F, & McManus MT 2013 Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. *PLoS Genet* **9** e1003569. (doi:10.1371/journal.pgen.1003569)

International HapMap Consortium 2005 A haplotype map of the human genome. *Nature* **437** 1299–1302. (doi:10.1038/nature04226)
ARRIVE guidelines to an in vivo database. *PloS Biology* **13** e1002151.

Keen RW, Hart DJ, Arden NK, Doyle DV & Spector TD 1999 Family history of appendicular fracture and risk of osteoporosis: a population-based study. *Osteoporosis International* **10** 161–166. 

Kelly PJ, Nguyen T, Hopper J, Pocock N, Sambrook P & Eisman J 1993 Changes in axial bone density with age: a twin study. *Journal of Bone and Mineral Research* **8** 11–17. 

Kennedy OD, Herman BC, Lauder DM, Majeska RJ, Sun HB & Schaffler MB 2012 Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenizing signal by distinct osteocyte populations. *Bone* **50** 1115–1122. 

Kornak U, Kasper D, Bosl MR, Kaiser E, Schweizer M, Schulz A, Friedrich W, Delling G & Jentsch TJ 2001 Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man. *Cell* **104** 205–215. 

Koscielny G, Yaikhom G, Iyer G, Veenhuis MF, Morgan H, Atienza-Herrero J, Kim JE, Nakashima K & de Crombrugghe B 2004 Transgenic mice lacking DMP1-targeted Cre expression in odontoblasts and osteocytes: a new tool to examine physiology and disease of postnatal bone and tooth. *American Journal of Pathology* **165** 1875–1882. 

Kornak U, Kaspar B, Hori M, Rosenthal N & Yerges-Armstrong LM 2011 The genetics of bone loss: implications for osteoporosis management. *Mayo Clinic Proceedings* **84** 632–637. 

Kim JE, Nakashima K & de Crombrugghe B 2004 Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth. *American Journal of Pathology* **165** 1875–1882.

Lacy DL, Boyle WJ, Simonet WS, Kostenuik PJ, Duyk GW, Sullivan JK, San Martin J & Dansey R 2012 Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. *Nature Reviews. Drug Discovery* **11** 401–419. 

Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Morgan H, Atienza-Herrero J, Kim JE, Nakashima K & de Crombrugghe B 2004 Transgenic mice lacking DMP1-targeted Cre expression in odontoblasts and osteocytes. *American Journal of Human Genetics* **74** 1115–1122. 

Liu Y, Xie Y, Zhang S, Dusevich V, Bonewald LF & Feng JQ 2007 DMP1-targeted Cre expression in osteoblasts and osteocytes. *Journal of Dental Research* **86** 320–325. 

Ley L, Boyle WJ, Simonet WS, Kostenuik PJ, Dougall WC, Sullivan JK, San Martin J & Dansey R 2012 Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. *Nature Reviews. Drug Discovery* **11** 401–419.

Mackar P, Delaroudis S & Anastasilakis AD 2015 Novel therapies for osteoporosis. *Metabolism* **64** 1199–1214. 

Manolio TA 2010 Genomewide association studies and assessment of the risk of disease. *New England Journal of Medicine* **363** 166–176. 

Marshall D, Johnell O & Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* **312** 1254–1259. 

Mitchell BD & Streeter EA 2013 Clinical impact of recent genetic discoveries in osteoporosis. *Application of Clinical Genetics* **6** 75–85. 

Mitchell BD & Yerges-Armstrong LM 2011 The genetics of bone loss: challenges and prospects. *Journal of Clinical Endocrinology and Metabolism* **96** 1258–1268. 

Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewer CP, Digby JE, Mohammed SN, Hurst JA et al. 1997 Congenital leptin deficiency is associated with severe early-onset obesity in humans. *Nature* **387** 903–908. 

Murray SA, Eppig JT, Smedley D, Simpson EM & Rosenthal N 2012 Beyond knockouts: cre resources for conditional mutagenesis. *Mammalian Genome* **25** 587–599. 

Nakanishi R, Aktyama H, Kimura H, Otsuki B, Shimizu M, Tsuboyama T & Nakamura T 2008 Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. *Journal of Bone and Mineral Research* **23** 271–277. 

Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF et al. 2011 Evidence for osteocyte regulation of bone homeostasis through RANKL expression. *Nature Medicine* **17** 1231–1234. 

Pangrango M, Pollani PL, Megarbane A, Lefranc G, Lanino E, Di Rocco M, Rucci F, Lucchini F, Ravanini M, Facchetti E et al. 2006 Mutations in OSTM1 (grey lethal) define a particularly severe form of autosomal recessive osteoporosis with neural involvement. *Journal of Bone and Mineral Research* **21** 1098–1105. 

Powell WF Jr, Barry KJ, Tulun I, Kobayashi T, Harris SE, Bringhurst FR & Pajevic PD 2011 Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. *Journal of Endocrinology* **209** 21–32. 

Raggett LJ & Partridge NC 2010 Cellular and molecular mechanisms of bone remodeling. *Journal of Biological Chemistry* **285** 25103–25108. 

Rivas RJ, Zheng HF & Spector TD 2012 Genetics of osteoporosis from genome-wide association studies: advances and challenges. *Nature Reviews Genetics* **13** 576–588. 

Robling AG, Nizolek PJ, Baldrigue LA, Condon KW, Allen MR, Alam I, Mantilla SM, Gluhak-Heinrich J, Bellido TM, Harris SE et al. 2008 Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. *Journal of Biological Chemistry* **283** 5866–5875. 

Roussepeu P & Van Zomeren B 1990 Unmasking multivariate outliers and leverage points. *Journal of the American Statistical Association* **85** 533–539. 

Sanchez-Fernandez MA, Sabichi S, Corea-Tapia M, Naumann R, Klemm J, Chambon P, Al-Robayti S, Blessing M & Hoflacque B 2012 Transgenic mice for a tamoxifen-induced, conditional expression of the Cre recombinase in osteoclasts. *PloS ONE* **7** e37592. 

Sander JD & Joung JK 2014 CRISPR-Cas systems for editing, regulating and targeting genomes. *Nature Biotechnology* **32** 347–355. 

Seeman E, Hopper JL, Bach LA, Cooper ME, Parkinson E, McKay J & Jerums G 1989 Reduced bone mass in daughters of women with osteoporosis. *New England Journal of Medicine* **320** 554–558. 

Shah AD, Shoiback D & Lewiecki EM 2015 Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis. *Expert Review of Endocrinology & Metabolism* **10** 471–481. 

Schofeld PN, Hoehndorf R & Gkoutos GV 2012 Mouse genetic and phenotypic resources for human genetics. *Human Mutation* **33** 826–836. 

Sharma JP & Saag KG 2014 Fracture mortality: associations with epidemiology and osteoporosis treatment. *Nature Reviews Endocrinology* **10** 592–602. 

Simonet WS, Lacey DL, Dunstan CR, Kelly M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T et al. 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Journal of Bone and Mineral Research* **12** 231–239. 

Skarnes WC, Rosen B, West AP, Koutsourakis M, Bushell W, Iyer V, Atienza-Herrero J, Kim JE, Nakashima K & de Crombrugghe B 2004 Transgenic mice lacking DMP1-targeted Cre expression in odontoblasts and osteocytes. *Journal of Dental Research* **86** 320–325. 

Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrango M, Susani L, Bredius R, Mancini G, Cant A, Bishop N et al. 2007 Osteocalc-poor...
human osteoporosis due to mutations in the gene encoding RANKL. Nature Genetics 39 960–962. (doi:10.1038/ng2076)
Svenson KL, Gatti DM, Valdar W, Welsh CE, Cheng R, Chesler EJ, Palmer AA, McMillan L & Churchill GA 2012 High-resolution genetic mapping using the mouse diversity outbred population. Genetics 190 437–447. (doi:10.1534/genetics.111.132597)
Sykes B, Oglivie D, Wordsworth P & Anderson & Jones N 1986 Osteogenesis imperfecta is linked to both type I collagen structural genes. Lancet 2 69–72. (doi:10.1016/0140-6736(86)91609-0)
Testa G, Schaft J, van der Hoeven F, Glaser S, Anastassiadis K, Zhang Y, Sykes B, Ogilvie D, Wordsworth P, Anderson & Jones N 1986 Osteogenesis imperfecta is linked to both type I collagen structural genes. Lancet 2 69–72. (doi:10.1016/0140-6736(86)91609-0)
van Dijk FS, Zillikens MC, Michaelis S, Cobben JM, et al. 2009 PPIB mutations cause severe osteogenesis imperfecta. American Journal of Human Genetics 85 521–527. (doi:10.1016/j.ajhg.2009.09.001)
van Dijk FS, Zillikens MC, Michäa D, Riesland M, Marcellis CL, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, et al. 2013 PL33 mutations in X-linked osteoporosis with fractures. New England Journal of Medicine 369 1529–1536. (doi:10.1056/NEJMoa1308223)
van Dijk FS, Zillikens MC, Micheila D, Riesland M, Marcellis CL, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, et al. 2013 PL33 mutations in X-linked osteoporosis with fractures. New England Journal of Medicine 369 1529–1536. (doi:10.1056/NEJMoa1308223)
van Dijk FL, Auger H, Lichtenbelt KD, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, et al. 2013 PL33 mutations in X-linked osteoporosis with fractures. New England Journal of Medicine 369 1529–1536. (doi:10.1056/NEJMoa1308223)
van Dijk FL, Auger H, Lichtenbelt KD, de Die-Smulders CE, Milbradt J, Franken AA, Harsevoort AJ, Lichtenbelt KD, et al. 2013 PL33 mutations in X-linked osteoporosis with fractures. New England Journal of Medicine 369 1529–1536. (doi:10.1056/NEJMoa1308223)
Vikman P, Freds J & Oskolkov N 2014 RNA sequencing: current and prospective uses in metabolic research. Journal of Molecular Endocrinology 53 R93–R101. (doi:10.1530/JME-14-0170)
Visscher PM, Brown MA, McCarthy MI & Yang J 2012 Five years of GWAS discovery. American Journal of Human Genetics 90 7–24. (doi:10.1016/j.ajhg.2011.11.029)
Waterston RH, Lindblad-Toh K, Birney E, Rogers J, Ablil JF, Agarwal P, Agarwala R, Ainscough R, Alexandersson M, An P, et al. 2002 Initial sequencing and comparative analysis of the mouse genome. Nature 420 520–526. (doi:10.1038/nature01262)
White JK, Gerdin AK, Karp NA, Ryder E, Buljan M, Bussell JN, Salisbury J, Clare S, Ingham NJ, Podrini C, et al. 2013 Genome-wide generation and systematic phenotyping of knockout mice reveals new roles for many genes. Cell 154 452–464. (doi:10.1016/j.cell.2013.06.022)
Wu S, Liu Y, Zhang L, Han Y, Liu Y & Deng HW 2013 Genome-wide approaches for identifying genetic risk factors for osteoporosis. Genome Medicine 5 44. (doi:10.1186/gm448)
Yamagata K, Oda N, Kaisaki PJ, Menzel S, Funuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Böttraj VV, et al. 1996 Mutations in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature 384 455–458. (doi:10.1038/384455a0)
Yoon BS, Ochinnikov DA, Yoshii I, Mishina Y, Behringer RR & Lyons KM 2005 Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. PNAS 102 5062–5067. (doi:10.1073/pnas.0500031102)
Yoshiki A & Moriwaki K 2006 Mouse phenotype research: implications of genetic background. ILAR Journal 47 94–102. (doi:10.1093/ilar.47.2.94)
Zhang M, Xuan S, Bouxsein ML, van Stechow D, Akeno N, Faugere MC, Piersma SR, Testa G, Schaft J, van der Hoeven F, Glaser S, Anastassiadis K, Zhang Y, Sykes B, Ogilvie D, Wordsworth P, Anderson & Jones N 1986 Osteogenesis imperfecta is linked to both type I collagen structural genes. Lancet 2 69–72. (doi:10.1016/0140-6736(86)91609-0)
Zheng HF, Forgetta V, Hsu YH, Estrada K, Rosello-Diez A, Leo PJ, Dahia CL, Park-Min KH, Tobias JH, Koooperberg C, et al. 2015 Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature 526 112–117. (doi:10.1038/nature14878)
Received in final form 11 August 2016
Accepted 17 August 2016
Accepted Preprint published online 17 August 2016